Literature DB >> 8115786

Staging of bladder cancer.

M K Gospodarowicz1.   

Abstract

The definitive diagnosis of bladder cancer is established at cystoscopic examination and confirmed by means of a transurethral biopsy. A careful bimanual palpation of the bladder under anesthesia is an integral part of the initial assessment of each patient. The most important part of the assessment of patients with bladder cancer is a thorough pathologic examination of the biopsy material establishing the histologic type of tumor, histologic grade, tumor configuration, depth of invasion of the bladder wall, and depth of the bladder wall available for assessment. If possible, the size of the tumor and the presence of associated carcinoma in situ should also be reported. Imaging studies play a smaller role in the clinical staging of bladder cancer. However, when initial staging procedures point to invasion of the muscularis propria, chest X-ray, bone scan, and computed tomography scan of the abdomen and pelvis may provide valuable information about possible metastases. Whereas the clinical staging is essential to select and evaluate therapy, the pathologic stage (pTNM) provides the most precise data with which to estimate prognosis and calculate end results. The pathologic assessment entails resection of the primary tumor or a biopsy adequate to evaluate the highest pT category, removal of lymph nodes adequate to validate the absence of regional lymph node metastasis, as well as biopsy and microscopic examination for assessment of distant metastases. Although numerous factors have an impact on the behaviour of the malignancy, in bladder cancer the anatomic extent of disease reflected in the current staging classification remains the most powerful indicator of outcome.

Entities:  

Mesh:

Year:  1994        PMID: 8115786     DOI: 10.1002/ssu.2980100109

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  4 in total

1.  SKIP expression is correlated with clinical prognosis in patients with bladder cancer.

Authors:  Longwang Wang; Mei Zhang; Yong Wu; Cheng Cheng; Yawei Huang; Zimin Shi; Hongwei Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

2.  NRP-1 expression in bladder cancer and its implications for tumor progression.

Authors:  Wen Cheng; Dian Fu; Zhi-Feng Wei; Feng Xu; Xiao-Feng Xu; You-Huang Liu; Jing-Ping Ge; Feng Tian; Cong-Hui Han; Zheng-Yu Zhang; Li-Ming Zhou
Journal:  Tumour Biol       Date:  2014-03-14

3.  High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy.

Authors:  Jianye Liu; Yonghong Li; Yiji Liao; Shijuan Mai; Zhiling Zhang; Zhouwei Liu; Lijuan Jiang; Yixin Zeng; Fangjian Zhou; Dan Xie
Journal:  Biomed Res Int       Date:  2013-09-04       Impact factor: 3.411

4.  Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.

Authors:  Jian-Ye Liu; Yong-Hong Li; Huan-Xin Lin; Yi-Ji Liao; Shi-Juan Mai; Zhou-Wei Liu; Zhi-Ling Zhang; Li-Juan Jiang; Jia-Xing Zhang; Hsiang-Fu Kung; Yi-Xin Zeng; Fang-Jian Zhou; Dan Xie
Journal:  BMC Cancer       Date:  2013-07-19       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.